



SAGE Therapeutics, Inc.
Investor Relations Department
215 First Street
Cambridge, MA 02142
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: SAGE


Last Trade:	84.94
Trade Time:	4:00 PM ET Jun 22, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	26.55 - 88.93
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare central nervous system, or CNS, disorders. Sage's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE) and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. Sage's proprietary chemistry platform has generated multiple new compounds that target GABAA and NMDA receptors, which are broadly accepted as impacting many psychiatric... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jun 12, 2017

[Sage Therapeutics Announces The Lancet Publishes Positive Phase 2 Brexanolone \(SAGE-547\) Clinical Data in Severe Postpartum Depression](#)

Jun 8, 2017

[Sage Therapeutics to Present at Goldman Sachs Healthcare Conference](#)

Jun 5, 2017

[Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

May 18, 2017

[Sage Therapeutics Receives Fast Track Designation for SAGE-217 for the Treatment of Major Depressive Disorder](#)

May 9, 2017

[Sage Therapeutics Announces First Quarter 2017 Financial Results and Provides Pipeline Update](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Feb 24, 2017

[Annual Report \(10-K\)](#)

Apr 28, 2017

[Proxy Statement \(DEF 14A\)](#)

May 10, 2017

[Quarterly Report \(10-Q\)](#)

Nov 3, 2016

[Quarterly Report \(10-Q\)](#)

Aug 9, 2016

[Quarterly Report \(10-Q\)](#)